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Introduction
In spite of abundant emerging data contributing to understanding of the molecular mechanisms of carcinogenesis and cancer prevention, the number of new diagnoses and death rates, especially in developing countries, continue to rise. In the People's Republic of China, cancer morbidity and mortality rates in 2009 were 285.91/100,000 and 180.54/100,000, respectively, which were higher than the rates of 250.03/100,000 and 166.22/100,000, respectively, in 2004. [1] [2] [3] Further, a 2012 US cancer report showed that approximately 1.6 million new cancer cases and 0.58 million cancer deaths were projected to occur in 2013. 4 Many factors, such as mutation, single nucleotide polymorphism (SNP), and epigenetic dysregulation of oncogene or tumor suppressor submit your manuscript | www.dovepress.com
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Ying et al gene, have been found to lead to activation of oncogene or expressed silence of tumor suppressor gene and eventually give rise to carcinogenesis. 5 Kras gene, a member of the Ras gene family, is one of the most important oncogenes in carcinogenesis and acts as an intracellular signal transducer. 6 It encodes a guanosine diphosphate (GDP)/GTP guanosine triphosphate (GTP)-binding protein that belongs to the small GTPase superfamily, regulates signal transduction, and is involved in cell proliferation and differentiation through Kras-related RAF/MEK/MAPK, AKT, and ERK pathways. [6] [7] [8] Mutation of the Kras oncogene plays a pivotal role in the pathogenesis of various solid tumors in humans, 9 with a 30%-60% mutation frequency detected in colorectal adenocarcinomas. 10 On the other hand, repression of Kras expression could inhibit tumor growth and invasion by small interfering RNA (siRNA) or microRNA (miRNA). 11 Let-7 miRNA posttranscriptionally regulates Kras oncogene expression by targeting the 3′-untranslated region (3′-UTR) of messenger RNA (mRNA) for degradation or translation repression. 12 Let-7 complementary binding site (LCS) SNPs, located in Kras gene 3′-URT, have been found to modulate the binding ability with let-7, 12 consequently resulting in aberrant expression of Kras gene. Thus, these loci are considered candidate genetic susceptibility factors for carcinogenesis.
Recently, emerging studies concerning let-7 LCS polymorphisms in Kras 3′-UTR, rs712 and rs61764370, reported that these SNPs increased risk of cancer and affected the survival of patients with malignant cancer using anti-epidermal growth factor receptor monoclonal antibody (EGFR) therapy in metastatic colorectal cancer (mCRC). 13, 14 However, other studies pertaining to these loci had conflicting conclusions. 15, 16 On the basis of accumulating evidence, a comprehensive meta-analysis of retrospective and prospective studies was conducted for the following purposes: 1) to evaluate the association of rs712 and rs61764370 with risk of cancer; and 2) to estimate the influence of rs61764370 genotypes on anti-EGFR treatment in mCRC.
Materials and methods
Study identification and selection
In this meta-analysis, relevant studies dating to November 2013 were searched for in the PubMed, Google Scholar, Embase, and Wanfang Data in accordance with the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. 17 Additional studies were identified by manual retrieval in order to obtain substantial articles. The following search terms were used: 1) "rs712, rs61764370 or LCS6 and tumor, cancer or carcinoma"; 2) "Kras polymorphism and tumor, cancer or carcinoma"; 3) "Let-7, Kras and tumor, cancer or carcinoma"; 4) "Let-7, Kras, LCS6 and cancer, EGFR". Relevant studies were first identified through review of each retrieved title and abstract. Then, relevant full-text studies were identified as eligible for meta-analysis according to the following inclusion criteria: 1) case control study concerning rs712, rs61764370, and cancer risk, or anti-EGFR therapy in mCRC, in English or Chinese; 2) cases were solid cancer patients and controls were cancer-free healthy individuals; 3) sufficient genotype frequency data were provided for calculating odds ratio (OR) and 95% confidence interval (CI); and 4) genotype distribution of the control group was consistent with Hardy-Weinberg equilibrium. Non-case control studies, reviews, comments, communications, metaanalyses, single-group design studies, and case control studies with duplicated data were excluded from this study.
Data extraction
Two investigators (Hou-Qun Ying and Feng Wang) independently extracted data from each study identified as eligible per the inclusion and exclusion criteria. A consensus was required for the inclusion of studies. From each eligible study, baseline characteristic data were extracted, which comprised the following: author name or abbreviated study name; year of publication; country; ethnicity; cases and controls; detection 
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Kras polymorphisms and cancer and a P-value of heterogeneity test (P H ) ,0.10 was considered significant heterogeneity. The fixed model was chosen to evaluate the combined data when the heterogeneity test was assumed to be homogenous; otherwise, the random model was used to estimate the overall effect. 20, 21 Stability of meta-analysis was estimated using sensitivity analysis by omitting each eligible study successively. Both Begg's funnel plot and Egger's test were used to establish possible publication bias, 21, 22 and asymmetry of funnel plot and P-value of Egger's test ,0.05 were considered to indicate the existence of publication bias. All calculations were performed using Stata (v 11.0; StataCorp LP, College Station, TX, USA) and RevMan (v 5.2; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software.
Results
eligible studies
The flowchart of the eligible study search is shown in Figure 1 . In total, 364 articles were obtained from the databases and by manual retrieval. According to the inclusion and exclusion criteria, 270 unrelated articles, 61 reviews and meta-analyses, 14 comments or communications, and one study with insufficient genotype data were excluded from the present study. As a result, a total of six case control studies 13, 15, [23] [24] [25] [26] concerning rs712 and cancer risk, 29 case control studies [27] [28] [29] [30] [31] [32] [33] [34] [35] relating to rs61764370 and cancer, and four studies 14, 16, 35, 36 concerning rs61764370 and anti-EGFR treatment in mCRC were enrolled as eligible studies. The baseline characteristics of eligible studies are listed in Tables 1 and 2 .
rs712 and cancer risk
The results of heterogeneity testing and overall effects of metaanalysis and Egger's test are listed in Table 3 . As shown in Table  3 and Figure 2 , no significant association was found between rs712 and risk of cancer in the overall population (P H =0. 27 
rs61764370 and cancer risk
Because of the low frequency of genotype GG in rs61764370, the majority of studies did not provide data for genotype GG, but, combining GG and GT, one single comparison (GT/GG versus TT) was evaluated in this locus. The comparison was analyzed in 29 studies, which included 14,796 cases and 147,985 controls. As shown in Table 3 and Figure 2, 
rs61764370 and response of anti-egFr treatment in mcrc
The association of rs61764370 and influence of anti-EGFR treatment in mCRC patients were estimated in combining with four original studies. Result in overall population showed that no statistically significant association was found between GT/GG genotype and response of mCRC treated with anti-EGFR (P H =0.003, OR =1.18, 95% CI =0.34-4.71) (Figure 3 ).
sensitivity analysis
The stability of this meta-analysis was examined to establish the influence of each eligible study on the pooled ORs by omitting a single study successively each time, and the corresponding pooled ORs were not materially changed in any comparison.
Publication bias
Possible publication bias was assessed using Begg's funnel plot and Egger's test. As shown in Table 3 and Figure 3 , the shapes of the funnel plots were symmetrical, and the P-values from the Egger's test indicated that no publication bias was found in any comparison.
Discussion
miRNA is an endogenous small non-coding RNA of 17-24 nucleotides that negatively regulates gene expression at the posttranscriptional level, predominantly by binding to the 3′-UTR of target mRNAs through nucleotide pairing. 37 It provides a wide range of functions in various physiological and pathological processes, including organ growth and development, cell proliferation and differentiation, and carcinogenesis and metastasis. [38] [39] [40] [41] Let-7, the first discovered miRNA family, which includes let-7a-g and i, has been verified as a tumor suppressor factor in various kinds of cancer.
12,42,43 Expression of Kras was downregulated through ten let-7 LCSs, which 
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Ying et al were found in Kras 3′-UTR. 30 SNPs of rs712 in LCS1 and rs61764370 in LCS6 can disrupt the let-7 binding site and decrease the combining capacity between them, contributing to aberrant Kras expression. 30 Increasing evidence shows two SNPs (rs712 and rs61764370) not only are associated with cancer, but also rs61764370 can modulate the anti-EGFR treatment response in mCRC. Meanwhile, contradictory results have been observed in other studies. 13, 14, 16 In the current study, the possible associations of rs712 and rs61764370 with risk of cancer and anti-EGFR therapy efficacy in mCRC were investigated by meta-analysis. The results showed that genotypes GT and GT/TT and allele T of rs712, 
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Ying et al and genotype GT/GG of rs61764370, were not associated with cancer, revealing that appearance of genotypes GT and GT/TT and the T allele of rs712 might not increase predisposition to cancer in the overall population and that genotype GT/GG of rs61764370 was not a genetic susceptibility factor for cancer in the Caucasian population. Significant associations were observed between genotype GT/TT and allele T of rs712 and risk of cancer in Chinese populations. The findings suggest that genotype GT/TT and allele T of rs712 could increase cancer risk and might be genetic susceptibility factors for cancer, only in the Chinese population. The following possible reasons might account for our findings. Due to differences in ethnic genetic backgrounds in Caucasian and Chinese populations, frequency of the G allele of rs61764370 in the Chinese population is less than 1%, and no study reported an association of this locus with cancer risk in the Chinese population. Although rs712 allele frequency in the Caucasian population is higher than 5%, only one eligible study 15 reported the association between rs712 and cancer risk in this population; therefore, small sample sizes of cases and controls in eligible studies may limit the power to reach a more precise result in Caucasian populations, for only one eligible study with sample size of cases and controls were less than 1000 concerning rs712 and cancer risk in Caucasian population. Moreover, on the basis of capability of let-7 regulating Kras expression, we deduced that the allele T of rs712 might disrupt and interfere with the combining capacity between let-7 and the 3′-URT of Kras mRNA and somehow lower the level of cellular let-7 concentration or reduce its activity. 30, 44 Due to loss of inhibition, expression of Kras is upregulated. Consequently, lower concentration or activity of let-7 and higher Kras-expressed p21 protein are involved in promoting cell proliferation and division, leading to carcinogenesis and metastases. 45, 46 Biological target treatment is an effective measure for malignant cancer therapy. Anti-EGFR monoclonal antibodies, cetuximab and panitumumab, are extensively used in mCRC therapy until now. Both mutation and SNP of Kras gene has been reported to affect response rates of mCRC treated with anti-EGFR. 47 Combining each including study, our metaanalysis results showed no statistically significant effect of genotype GT/GG of rs61764370 on response rates of mCRC patients treated with anti-EGFR, suggesting that genotype GT/GG does not influence the anti-EGFR therapy response in mCRC, thus should not be considered a predictor of the efficacy of anti-EGFR therapy in mCRC.
The current meta-analysis is, to our knowledge, the first assessment of the relationship between Kras polymorphism and risk of cancer, as well as the first assessment of treatment of anti-EGFR in mCRC, and provides a more reliable estimation of the association between rs712, rs61764370 and cancer risk as well as response to anti-EGFR therapy in mCRC patients when compared with any single study with small samples. However, there are several limitations of the meta-analysis, which should be addressed. First, retrieval of eligible studies was only performed in PubMed, Google Scholar, Embase, and Wanfang databases in English and Chinese, which means eligible studies published in other languages may have been overlooked, which could have led to selection bias. Second, small numbers of cases (,1,000) in the majority of eligible studies decreased the statistical power. Third, the sample size of this meta-analysis is the largest of sample size in the Meta-analysis so far, but it was neither large nor comprehensive enough to allow for a precise conclusion to be reached, especially in Chinese or Caucasian population. Finally, due to unavailable data in some included studies, we could not perform a meta-analysis based on adjustments for age, diet, smoking, or other environmental factors.
Conclusion
Genotype GT/TT and allele T of rs712 may be potential risk factors for developing cancer in the Chinese population, while GT/GG of rs61764370 neither increases predisposition to cancer in Caucasian people nor predicts clinical outcome of anti-EGFR therapy in mCRC. Given the limitations of the current study, a larger sample size and functional analysis are warranted to further validate the results.
